Press release
Metastatic HER2-positive Breast Cancer Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Eli Lilly, Genentech, Kadcyla, MacroGenics, Merck, Novartis, Pfizer, Puma Biotechnology, Roche, Seattle Genetics
DelveInsight's "Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic HER2-positive Breast Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Metastatic HER2-positive Breast Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic HER2-positive Breast Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Metastatic HER2-positive Breast Cancer: An Overview
HER2-Positive Breast Cancer is a type of breast cancer in which breast cancer cells test shows positive status for a protein receptor called human epidermal growth factor receptor 2. The normal function of this protein is to control how a healthy breast cell grows, divides, and repairs itself.
But when there is a mutation in the gene that controls the HER2 protein, also known as erythroblastic oncogene B (ERBB2) gene, the body creates too many HER2 receptors, which results in uncontrollable breast cell growth and division. The most common signs of this indication are breast swelling, change in the shape of the breast, skin irritation or dimpling, pain in the breast, and redness or thickness of the breast skin. Diagnosis of HER2-positive breast cancer is made by following recommended tests, such as the IHC test, the FISH test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests use antibodies or DNA to stain the cancer cells.
Metastatic HER2-positive Breast Cancer Market Key Facts
• According to the American Institute for Cancer Research, there were over 2 million new cases of breast cancer in 2018 worldwide. The age-standardized rate of breast cancer in women in the United Kingdom alone is 93.6 per 100,000.
• As per a study conducted by Howlader et al. titled "US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status", among case patients with known HR/HER2 status, 5240 (10.3%) were found to be HR-positive/HER2-positive and 2328 (4.6%) were HR-negative/HER2-positive.
Discover How Metastatic HER2-positive Breast Cancer Market Will Grow by 2032:
https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic HER2-positive Breast Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic HER2-positive Breast Cancer therapies in the market. It also provides a detailed assessment of the Metastatic HER2-positive Breast Cancer market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the market trend for each marketed Metastatic HER2-positive Breast Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Metastatic HER2-positive Breast Cancer Epidemiology
The epidemiology section covers detailed insights into the historical, and current Metastatic HER2-positive Breast Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Metastatic HER2-positive Breast Cancer Epidemiology Segmented as -
• Total Incidence of Breast Cancer (2019-2032)
• Total Incidence of Metastatic Breast Cancer (2019-2032)
• Stage-specific Incidence of Breast Cancer (2019-2032)
• Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER+] (2019-2032)
Get Key Insights Into the Evolving Metastatic HER2-positive Breast Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to be launched during the study period. The analysis covers the market share by Metastatic HER2-positive Breast Cancer drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic HER2-positive Breast Cancer Therapeutics Assessment
The introduction of anti-HER2 therapies for the treatment of patients with HER2-Positive Metastatic Breast Cancer has led to dramatic improvements in survival in both early and advanced settings. Despite, having currently available anti-HER2 therapies that have changed the natural history of HER2-Positive Metastatic Breast Cancer, new therapeutic options are necessary because the disease is essentially incurable in the metastatic setting and a relevant proportion of patients with early-stage disease still relapse in spite of the use of currently available therapies.
Key players, such as MacroGenics, Roche/ Genentech, Pfizer, Merck Sharp & Dohme, Eli Lilly and Company, along with a few others are involved in developing therapies for HER-2 Positive Metastatic Breast Cancer.
Leading Companies in the Metastatic HER2-positive Breast Cancer Therapeutics Market Include
• Eli Lilly and Company
• Genentech
• Kadcyla
• MacroGenics
• Merck Sharp & Dohme
• Novartis Pharmaceuticals
• Pfizer
• Puma Biotechnology
• Roche
• Seattle Genetics
And many others
Emerging and Marketed Metastatic HER2-positive Breast Cancer Therapies Covered in the Report Include
• Abemaciclib (LY2835219): Eli Lilly and Company
• Ibrance (Palbociclib): Pfizer
• Kadcyla (Ado-trastuzumab emtansine): Kadcyla
• Keytruda (Pembrolizumab): Merck Sharp & Dohme
• Margetuximab: MacroGenics
• Nerlynx (Neratinib): Puma Biotechnology
• Perjeta (Pertuzumab): Genentech
• Tecentriq (Atezolizumab): Roche/ Genentech
• Trastuzumab: Roche
• Tukysa (Tucatinib): Seattle Genetics
• Tykerb (Lapatinib): Novartis Pharmaceuticals
And many more
Learn More About the Emerging Therapies & Key Companies in the Metastatic HER2-positive Breast Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic HER2-positive Breast Cancer Competitive Intelligence Analysis
4. Metastatic HER2-positive Breast Cancer Market Overview at a Glance
5. Metastatic HER2-positive Breast Cancer Background and Overview
6. Metastatic HER2-positive Breast Cancer Patient Journey
7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population
8. Metastatic HER2-positive Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic HER2-positive Breast Cancer Unmet Needs
10. Key Endpoints of Metastatic HER2-positive Breast Cancer Treatment
11. Metastatic HER2-positive Breast Cancer Marketed Products
12. Metastatic HER2-positive Breast Cancer Emerging Therapies
13. Metastatic HER2-positive Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic HER2-positive Breast Cancer Market Outlook (7 major markets)
16. Metastatic HER2-positive Breast Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic HER2-positive Breast Cancer Market.
18. Metastatic HER2-positive Breast Cancer Market Drivers
19. Metastatic HER2-positive Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market
Dysfunctional Uterine Bleeding Market
https://www.delveinsight.com/report-store/dysfunctional-uterine-bleeding-market
Status Epilepticus Market
https://www.delveinsight.com/report-store/status-epilepticus-market
Brain Hemorrhage Market
https://www.delveinsight.com/report-store/brain-hemorrhage-market
Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
Ductal Carcinoma in Situ Market
https://www.delveinsight.com/report-store/ductal-carcinoma-in-situ-market
Electroencephelographs (EEG) Pipeline Insight
https://www.delveinsight.com/report-store/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape
Spinal Decompression/Traction Devices Market
https://www.delveinsight.com/report-store/spinal-decompression-traction-devices-market
Bronchopulmonary Dysplasia Market
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
Drug Hypersensitivity Market
https://www.delveinsight.com/report-store/drug-hypersensitivity-market
Familial Chylomicronemia Syndrome (FCS) Market
https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
Postmyocardial Infarction Syndrome Market
https://www.delveinsight.com/report-store/postmyocardial-infarction-syndrome-market
Surgery and Radiation Therapy in Brain Cancer Market
https://www.delveinsight.com/report-store/surgery-and-radiation-therapy-in-brain-cancer-market
Acute ischemic stroke (AIS) Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market
Hemophagocytic Lymphohistiocytosis Market
https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market
Staphylococcus Aureus Infection Market
https://www.delveinsight.com/report-store/staphylococcus-aureus-infection-market
Treatment-Resistant Hypertension Market
https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market
Urticaria Or Hives Market
https://www.delveinsight.com/report-store/urticaria-or-hives-market
Acute Heart failure Market
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
Bowen's Disease Market
https://www.delveinsight.com/report-store/bowens-disease-market
Contrast-Induced Nephropathy Market
https://www.delveinsight.com/report-store/contrast-induced-nephropathy-market
Delirium Market
https://www.delveinsight.com/report-store/delirium-market
Dry AMD MarketEGFR Inhibitors-Induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
Excessive Daytime Sleepiness (EDS) Market
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market
Gene and Cell Therapies Targeting CNS Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market
Glioma Market
https://www.delveinsight.com/report-store/glioma-market
Graves Ophthalmopathy Market
https://www.delveinsight.com/report-store/graves-ophthalmopathy-market
H3N2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
Nontuberculous Mycobacterial (NTM) Infections Market
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market
Pneumothorax Treatment Devices Market
https://www.delveinsight.com/report-store/pneumothorax-treatment-devices-market
Portal Hypertension Market
https://www.delveinsight.com/report-store/portal-hypertension-market
Decompensated Cirrhosis Market
https://www.delveinsight.com/report-store/decompensated-cirrhosis-market
Follicular Lymphoma Market
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights
Osteochondromas Market
https://www.delveinsight.com/report-store/osteochondromas-market
Hidradenitis Suppurativa Market
https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
IgG4-Related Disease Market
https://www.delveinsight.com/report-store/igg4-related-disease-market
Lichen Planus Market
https://www.delveinsight.com/report-store/lichen-planus-market
Retinal Vein Occlusion Market
https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Meniere's Disease Market
https://www.delveinsight.com/report-store/menieres-disease-md-market
Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market
Angelman Syndrome Market
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
Eosinophilic Gastroenteritis (EGE) Market
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market
Hereditary Transthyretin Amyloidosis (hATTR) Market
https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market
Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
Post-Operative Cataract Surgery Inflammation Market
https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market
Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic HER2-positive Breast Cancer Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Eli Lilly, Genentech, Kadcyla, MacroGenics, Merck, Novartis, Pfizer, Puma Biotechnology, Roche, Seattle Genetics here
News-ID: 3169478 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
